UroGen Pharma Stock: An Emerging GARP Stock (NASDAQ:URGN)
· seekingalpha.com
UroGen Pharma (URGN) stock dipped 30% after a 208% rally—see why Zusduri’s launch, reimbursement, and patents could fuel growth.
Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a m...